Otolaryngology · Frisco, TX
NPI
1437153418
Since 2005
Specialty
Otolaryngology
Code 207Y00000X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
4401 Coit Rd, Suite 411
Frisco, TX, 75035
Phone (972) 731-7654
Groups this clinician bills Medicare through
Medicare paid, 2024
$235K
3,011 services
Medicare patients, 2024
549
Average age 76
Drug cost, 2024
$33K
1,375 prescriptions
Company payments, 2025
$586
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Lav A Kapadia was code 31231 (nasal/sinus endoscopy), 250 times for 162 patients. In total Lav A Kapadia billed 3,011 services in 61 codes, and Medicare paid $235K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-05-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 31231 Nasal/Sinus Endoscopy | Office | 250 | 162 | $147.97 | $37K |
| 99214 Office E&M - Established | Office | 232 | 185 | $95.24 | $22K |
| 99213 Office E&M - Established | Office | 225 | 164 | $68.54 | $15K |
| 69210 Other Organ Systems | Office | 196 | 147 | $33.99 | $6,662 |
| 99204 Office E&M - New | Office | 156 | 156 | $123.42 | $19K |
| 31575 Other Organ Systems | Office | 134 | 115 | $98.23 | $13K |
| 70486 CT/CTA - Head and Neck | Office | 120 | 111 | $102.13 | $12K |
| 99215 Office E&M - Established | Office | 118 | 96 | $133.81 | $16K |
| 99203 Office E&M - New | Office | 62 | 62 | $79.95 | $4,957 |
| 99212 Office E&M - Established | Office | 60 | 48 | $40.55 | $2,433 |
| 99205 Office E&M - New | Office | 55 | 55 | $154.97 | $8,523 |
| 95992 Treatment - Miscellaneous | Office | 36 | 29 | $29.95 | $1,078 |
| 76536 Ultrasound - Nonspecific | Office | 12 | 12 | $73.88 | $887 |
| 30140 Other Organ Systems | Facility | 11 | 11 | $112.33 | $1,236 |
| 30520 Other Organ Systems | Facility | 11 | 11 | $508.95 | $5,598 |
By year: 2022 $172K for 2,329 services; 2023 $230K for 2,418 services; 2024 $235K for 3,011 services.
Medicare prescription drug claims, 2024
In 2024, the drug Lav A Kapadia prescribed most often to Medicare patients was Ipratropium Bromide, with 511 prescriptions and refills. In total Lav A Kapadia wrote 1,375 Medicare prescriptions that cost $33K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ipratropium Bromide Generic | 511 | 657 | 223 | $12K |
| Mupirocin Generic | 153 | 157 | 91 | $1,104 |
| Ofloxacin Generic | 82 | 82 | 60 | $1,666 |
| Prednisone Generic | 77 | 77 | 71 | $140 |
| Omeprazole Generic | 62 | 106 | 27 | $1,239 |
| Cefdinir Generic | 54 | 54 | 44 | $1,211 |
| Ondansetron Odt Ondansetron | 38 | 38 | 37 | $343 |
| Azithromycin Generic | 34 | 34 | 30 | $404 |
| Prednisolone Generic | 32 | 32 | 23 | $3,309 |
| Fluticasone Propionate Generic | 30 | 33 | 12 | $321 |
| Methylprednisolone Generic | 28 | 28 | 24 | $168 |
| Fluocinolone Acetonide Oil Generic | 27 | 29 | 22 | $1,262 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 26 | 26 | 23 | $381 |
| Diazepam Generic | 20 | 20 | 13 | $32.2 |
| Triamterene-Hydrochlorothiazid Triamterene/Hydrochlorothiazid | 18 | 51 | Under 11 | $201 |
Brand drugs: 26 claims; generic drugs: 1,349 claims; opioid claims: 27.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Lav A Kapadia $586 ($586 in general payments such as food, travel and fees) from 9 companies. The largest payer was Medtronic, Inc. with $302.
| Company | Payments | Amount |
|---|---|---|
| Medtronic, Inc. MDT | 2 | $302 |
| Sanofi-Aventis U.S. LLC SNY | 1 | $98.99 |
| Inspire Medical Systems, Inc. INSP | 2 | $64.1 |
| Integra LifeSciences Corporation IART | 1 | $39.28 |
| Optinose US, Inc. | 1 | $20.11 |
| GlaxoSmithKline, LLC. GSK | 1 | $18.08 |
| Stryker Corporation SYK | 1 | $15.24 |
| Regeneron Healthcare Solutions, Inc. REGN | 1 | $14.5 |
| AYTU BioPharma, Inc. AYTU | 1 | $13.63 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.